Navigation Links
Gene therapy for metastatic melanoma in mice produces complete remission
Date:11/18/2010

INDIANAPOLIS A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation. The online version is now available.

Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem cells of mice. Hematopoietic stem cells are the bone marrow cells that produce all blood and immune system cells.

The T cell gene, which recognizes a specific protein found on the surface of melanoma, was isolated and cloned from a patient with melanoma. The gene-modified stems cells were then transplanted back into hosts and found to eradicate metastatic melanoma for the lifetime of the mice.

"We found that the transplantation of gene-modified hematopoietic stem cells results in a new host immune system and the complete elimination of tumor," reported Christopher E. Touloukian, M.D., an assistant professor of surgery and immunology at the IU School of Medicine and a member of the Indiana University Melvin and Bren Simon Cancer Center. "To date, cancer immunotherapies have been hampered by limited and diminishing immune responses over time. We believe this type of translational model opens new doors for patients with melanoma and potentially other cancers by taking advantage of the potent regenerative capacity of hematopoietic stem cells and new advances in gene therapy."

This research was funded by a National Institutes of Health grant.

It has paved the way for a new clinical trial in humans funded by the V Foundation for Cancer Research. The pilot phase I trial will involve treatment of 12 patients and focus primarily on the safety and efficacy of the therapy, said Dr. Touloukian, who is the senior author on the JCI paper and the principal investigator for the clinical study. The clinical trial is expected to begin accruing patients by late 2011.

In 2010, more than 68,000 patients will be diagnosed with melanoma and the disease will be associated with approximately 9,000 deaths. The state of Indiana has the 11th highest rate of melanoma incidence of all 50 states. Current treatments for metastatic melanoma, though exciting and innovative, have been highly toxic and largely unsuccessful with the most patients dying within 6 to 12 months after diagnosis.


'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related medicine news :

1. Neuralstem files FDA application for first drug therapy
2. Combination therapy improves survival time for patients with advanced liver cancer
3. Gene Therapy Shows Potential Against Heart Failure
4. Hearing loss common following radiation therapy for head and neck cancer
5. Targeted therapy reactivates guardian of the genome in resistant cancer
6. GUMC: fMRI predicts outcome to talk therapy in children with an anxiety disorder
7. Colorectal cancer risk increases in prostate cancer patients on androgen deprivation therapy
8. Fracture Risk Seen With Hormone Therapy for Prostate Cancer
9. Menopausal hormone therapy may increase risk of ovarian cancer
10. Side effects of hormonal breast cancer therapy increased; may affect treatment adherence
11. Potential drug therapy for diabetic retinopathy under study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene therapy for metastatic melanoma in mice produces complete remission
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the ... are currently accepting new patients at their practice for these custom clear aligners. These ... is why they offer the latest in modern dental techniques to ensure that all ...
(Date:6/20/2017)... Ariz. (PRWEB) , ... June 20, 2017 , ... ... Natural Brands®, makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted ... Sun Corridor Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other ...
(Date:6/20/2017)... ... ... John D'Eri, CEO of Rising Tide Car Wash , will accept ... the Autism Society of America 's 49th annual conference to be held this ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively on ...
(Date:6/20/2017)... ... ... The law firm of Momkus McCluskey Roberts LLC congratulates attorney ... Bar Association’s Board of Directors. Cassioppi officially took on the leadership role during the ... Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as the DCBA’s ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... new operating rooms this month. These additions will expand the capabilities of the ... facilities. One operating room will be solely dedicated to pediatric operations, while the ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
(Date:6/8/2017)... , June 8, 2017   Responding to Heath ... and the death of singer Chris Cornell in ... Rights International offers a free online psychiatric ... consumers and families about psychotropic drug risks. ... who died from an accidental overdose, has called for tighter ...
Breaking Medicine Technology: